International Conferences

Recommended Conferences for Mood Disorder

Mood Disorder

---

Omics International publishes 304 Open Access Articles in 13 International Journals it has 32 Upcoming Conferences and 15 Previous Conferences with 581 Conference Proceedings and 92 National symposiums so far in the field.

About 20% of the U.S. population reports at least one depressive symptom in a given month, and 12% report two or more in a year. A survey conducted in 1992 found rates of major depression reaching 5% in the previous 30 days, 17% for a lifetime. Mood disorder is less common, occurring at a rate of 1% in the general population, but some believe the diagnosis is often overlooked because manic elation is too rarely reported as an illness.

Mood disorders represent a category of mental disorders in which the problem primarily affects a person’s persistent emotional state (their mood). Marked by changes in mood, depression and bipolar disorder (also known as manic depression) are both highly treatable, medical illnesses. Unfortunately, many people don't get the help they need because of the misunderstanding surrounding the illnesses or the fear associated with stigma.

About Omics

 OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker. 

Scope & Importance of Mood Disorders

The majority of people with mood disorders are able to find treatments that work. Talk therapy, medication or a combination of both help individuals feel better and change situations in their lives that may be contributing to their illnesses. The global market for drugs used to treat Mood disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly too nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018.

List of Best International Conferences:

• 5^th Neurology Congress March 14-16, 2016 London, UK
• 2^nd Parkinson’s Disease and Movement Disorders Conference November 28-30, 2016 Chicago, USA
• 2^nd Brain Disorders Conference October 27-29, 2016 Chicago, USA
• Dual diagnosis Conference July 21-22, 2016 Chicago, USA
• Neuro Rehabilitation Conference July 21-22, 2016 Brisbane, Australia
• 6^th  Neurological conference  May 19-21, 2016 San Antonio, USA
• 4^th Vascular Dementia Conference June 30-July 2, 2016 Valencia, Spain
• 2^nd Epilepsy Conference October 24-26, 2016 Rome, Italy
• 2^nd Depression, Anxiety and Stress Management Meeting November 3-4, 2016 Valencia, Spain
• 5^th Alzheimer’s Disease and Dementia Conference September 29-Oct 1, 2016 London, UK
• 2^nd Neurological Disorders and Stroke Conference April 28-30, 2016 Dubai, UAE
• ANXIETY AND DEPRESSION CONFERENCE
• Mood and Anxiety Disorders Conference
• Annual Perinatal Mood Disorders Conference

Related Associations and Societies

·         Mental Health America

·         Canadian Mental Health Association

·         Mood Disorders Association of Ontario

·         Mood Disorders Association of British Columbia

·         Health and Canadian Society

·         American Clinical Neurophysiology Society

·         American Academy of Neurology

·         European Neurological Societies

·         World Federation of Neurology

·         Spanish Society of Neurology

·         Hilarescere Foundation in Italy

·         Italian MS society in Italy   

·         Southern Clinical Neurological Society

·         ESNR European Society of Neuroradiology

·         Vision sciences society

·         American Association of Neurological Surgeons

·         Saudi Association of Neurosurgery

·         Emirates Medical Association

Top Market key players:

·         AstraZeneca plc

·         Eli Lilly & Co

·         Johnson & Johnson

·         Pfizer

·         GlaxoSmithKline

·         Novartis AG

·         Sanofi

·         Merck & Co

·         Abbott Laboratories

·         UCB

·         Bristol-Meyers Squibb Co

·         Astellas Pharma

·         Cordis Corporation

·         Boston Scientific Corporation

·         Siemens AG

·         Genentech, Inc

·         Koninklijke Philips N.V

·         Medtronic plc

·         GE Healthcare

·         Stryker Corporation

·         Abbvie

·         Impax labs

·         Hospira

·         Genzyme

·         Forest Laboratories

·         Chelsea therapeutics

·          Upshers-smith laboratories

Market analysis for Stress Management:

School and college students, graduates, research workers, and even highly qualified professionals knowingly or unknowingly suffer from stress. Be it a developed or a developing nation, depression and stress prevails in the roots. Various studies reveal that even in countries like USA, 10-15% of population remains depressed at any given time of the year. Three times more women than men are diagnosed and average duration is of 10 years. Even in UK and Germany, more than 50% youngsters fall in the state of depression. They are stressed in the run for more money and better life style. People from other nations like Greece, Spain, Portugal, Italy, France, India, Bangladesh, Pakistan etc. are mainly stressed because of unemployment, poverty and poor health. Sress Management 2016 is therefore an innitiative to gather the represantatives from all these nations to share their research and knowledge on "Novel Discoveries and Strategies to Manage Depression, Anxiety and Stress.

This page will be updated regularly.

This page was last updated on April 26, 2024